Vivos Therapeutics, Inc. (VVOS)
NASDAQ: VVOS · Real-Time Price · USD
2.630
-0.080 (-2.95%)
At close: Apr 25, 2025, 4:00 PM
2.380
-0.250 (-9.51%)
Pre-market: Apr 28, 2025, 5:22 AM EDT
Vivos Therapeutics Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for Vivos Therapeutics stock have an average target of 6.10, with a low estimate of 6.00 and a high estimate of 6.20. The average target predicts an increase of 131.94% from the current stock price of 2.63.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Vivos Therapeutics stock from 2 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 | 2 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Ascendiant Capital | Ascendiant Capital | Strong Buy Maintains $6.6 → $6.2 | Strong Buy | Maintains | $6.6 → $6.2 | +135.74% | Apr 15, 2025 |
| Ascendiant Capital | Ascendiant Capital | Strong Buy Reiterates $6.6 | Strong Buy | Reiterates | $6.6 | +150.95% | Nov 20, 2024 |
| Alliance Global Partners | Alliance Global Partners | Strong Buy Maintains $8.25 → $6 | Strong Buy | Maintains | $8.25 → $6 | +128.14% | Nov 19, 2024 |
| Ascendiant Capital | Ascendiant Capital | Strong Buy Maintains $6.4 → $6.6 | Strong Buy | Maintains | $6.4 → $6.6 | +150.95% | Aug 20, 2024 |
| Ascendiant Capital | Ascendiant Capital | Strong Buy Initiates $63 | Strong Buy | Initiates | $63 | +2,276.43% | Jan 17, 2023 |
Financial Forecast
Revenue This Year
18.51M
from 15.03M
Increased by 23.17%
Revenue Next Year
23.18M
from 18.51M
Increased by 25.23%
EPS This Year
-1.30
from -2.22
EPS Next Year
-0.51
from -1.30
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 |
|---|---|---|
| High | 19.2M | 23.9M |
| Avg | 18.5M | 23.2M |
| Low | 17.6M | 22.3M |
Revenue Growth
| Revenue Growth | 2025 | 2026 |
|---|---|---|
| High | 27.8% | 28.9% |
| Avg | 23.2% | 25.2% |
| Low | 17.4% | 20.3% |
EPS Forecast
| EPS | 2025 | 2026 |
|---|---|---|
| High | -1.05 | -0.53 |
| Avg | -1.30 | -0.51 |
| Low | -1.51 | -0.49 |
EPS Growth
| EPS Growth | 2025 | 2026 |
|---|---|---|
| High | - | - |
| Avg | - | - |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.